Philip Wendschuh
Cardiovascular Disease · Lorain, OHNPI 1548249741
Payments from drug & device makers
Across 131 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$278
- Amgen$276
- Abbott$243
- Astellas Pharma US Inc$238
- Boehringer Ingelheim$215
- Medtronic$205
- plus $1K from 18 others
What the payments were for
- Consulting fees$70%
- Food & beverage$2,45692%
- Education$1987%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 15 | $278 |
| Amgen | 11 | $276 |
| Abbott | 6 | $243 |
| Astellas Pharma US Inc | 6 | $238 |
| Boehringer Ingelheim | 12 | $215 |
| Medtronic(2 entities) | 6 | $205 |
| Boston Scientific | 9 | $164 |
| Novartis | 9 | $158 |
| Amarin Pharma, Inc. | 9 | $149 |
| Sanofi-aventis U.S. LLC | 9 | $132 |
| AstraZeneca | 7 | $115 |
| Lundbeck LLC | 5 | $92 |
| E.r. Squibb & Sons, L.L.C. | 5 | $71 |
| Pfizer | 5 | $61 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $46 |
| Philips North America LLC | 2 | $42 |
| Kowa Pharmaceuticals America, Inc. | 3 | $39 |
| Actelion Pharmaceuticals US, Inc. | 2 | $37 |
| Regeneron Healthcare Solutions, Inc. | 2 | $34 |
| Esperion Therapeutics, Inc. | 1 | $21 |
| Aegerion Pharmaceuticals, Inc. | 1 | $13 |
| Vifor Pharma, Inc. | 1 | $12 |
| Merck | 1 | $11 |
| Z-medica, LLC | 1 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,662 in reported general payments places this provider in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 35 | $35,951 |
| XareltoRivaroxaban | 15 | $21,288 |
| Ranolazine ErRanolazine | 18 | $2,069 |
| Metoprolol Succinate | 81 | $1,339 |
| Potassium Chloride | 44 | $921 |
| Losartan Potassium | 73 | $714 |
| Atorvastatin Calcium | 62 | $652 |
| Isosorbide Mononitrate ErIsosorbide Mononitrate | 42 | $626 |
| ClopidogrelClopidogrel Bisulfate | 45 | $483 |
| Rosuvastatin Calcium | 34 | $416 |
| Pravastatin Sodium | 29 | $340 |
| Amlodipine Besylate | 57 | $339 |
| Carvedilol | 29 | $234 |
| Hydralazine Hcl | 29 | $226 |
| Spironolactone | 17 | $181 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $61 | $35,95135 claims |
| Johnson & JohnsonXarelto | $278 | $21,28815 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 827 cardiovascular disease providers in Ohio.
Other cardiovascular disease in Lorain
- Samir KapadiaCleveland$11.1M
- Steven NissenCleveland$5.3M
- Milind DesaiCleveland$5M
- Abraham LincoffCleveland$3.6M
- Carlos HubbardCleveland$3.1M
- Guilherme AttizzaniCleveland$2.8M
- Wai Hong TangCleveland$2.2M
- Bhola RamaMarion$2.1M
- Mazen HannaCleveland$1.6M
- Akber MohammedSpringfield$1.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.